Skip to main content
SpringerLink
Log in

Changes in Neuroglial Interactions in Nigrostriatal Brain Structures on Modeling of Dopamine System Dysfunction

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Hypofunction of the dopamine system was induced by prolonged administration of reserpine or haloperidol in Wistar rats. Reserpine increased the number of astrocytes containing glial fibrillary acidic protein in the striatum by 49%, but decreased the number of astrocytes containing glutamine synthase by 23% and reduced monoamine oxidase B activity by one third. Haloperidol had no significant effect on morphochemical measures of astrocytes but increased the number of oligodendrocytes. It is suggested that activation of astroglial cells by reserpine in a model of dopamine hypofunction is induced by metabolic impairment in the corticostriate glutamatergic system resulting from suppression of dopaminergic transmission in the basal nuclei. Changes in neuroglial interactions in the striatum, leading to imbalance of neurotransmitter systems, may underlie dysfunction of the basal nuclei in a number of human diseases, including Parkinson’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. V. Z. Gorkin, L. I. Gridneva, and I. V. Verevkina, Contemporary Methods in Biochemistry,V. N. Orekhovich (ed.), Meditsina, Moscow (1967), pp. 155–177.

    Google Scholar 

  2. E. L. Dovedov, D. N. Voronkov, and R. M. Khudoerkov, “Transient exposure to haloperidol and reserpine on dopamine metabolism in the nigrostriatal system of the brain in rats,” Byull. Eksperim. Biol. Med., No. 8, 151–154 (2010).

  3. M. F. Mineeva-Vyalykh, “A method for the direct spectrophotometric estimation of the rate of the tyrosine hydroxylase reaction,” Vopr. Med. Khim., No. 2, 274–279 (1976).

  4. R. M. Khudoerkov, D. N. Voronkov, and N. G. Yamshchikova, “Immunohistochemical and morphological changes to neurons and neuroglia in nigrostriatal structures of the brain in modeling of neurodegeneration of the substantia nigra,” Byull. Eksperim. Biol. Med., No. 6, 876–880 (2012).

  5. I. S. Boksha, E. B. Tereshkina, and G. S. Burbaeva, “Glutamine synthetase and glutamine synthetase-like protein from human brain: purification and comparative characteristics,” J. Neurochem., No. 6, 2574–2582 (2000).

  6. G. S. Burbaeva, I. S. Boksha, E. B. Tereshkina, et al., “Systemic neurochemical alterations in schizophrenic brain: glutamate metabolism in focus,” Neurochem. Res., No. 9, 1434–1444 (2007).

  7. J. De Keyser, J. P. Mostert, and M. W. Koch, “Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders,” J. Neurol. Sci., 267, 30–16 (2008).

    Google Scholar 

  8. J. Ekblom, S. S. Jossan, M. Bergström, et al., “Monoamine oxidase-B in astrocytes,” Glia, No. 2, 122–132 (1993).

  9. J. G. Emsley and J. D. Macklis, “Astrocyte heterogeneity closely reflects the neuronal-defined anatomy of the adult murine CNS,” Neuron Glia Biol., No. 3, 175–186 (2006).

  10. V. Eulenburg and J. Gomeza, “Neurotransmitter transporters expressed in glial cells as regulators of synapse function,” Brain Res. Rev., No. 1–2, 103–112 (2010).

  11. M. N. Gordon,W. A. Schreier, X. Ou, et al., “Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat,” J. Comp. Neurol., No. 1, 106–119 (1997).

  12. K. Håkansson, L. Pozzi, A. Usiello, et al., “Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol,” Eur. J. Neurosci., No. 4, 1108–1112 (2004).

  13. J. K. Mallajosyula, D. Kaur, S. J. Chinta, et al., “MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology,” PLoS One, No. 2, 1616 (2008).

  14. M. F. Mazurek, S. M. Savedia, R. S. Bobba, et al., “Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal,” J. Neurol. Neurosurg. Psychiatry, No. 6, 799–801 (1998).

  15. P. L. McGeer and E. G. McGeer, “Glial reactions in Parkinson’s disease,” Mov. Disord., No. 4, 474–483 (2008).

  16. G. M. Petzinger and M. W. Jakowec, “Animal models of Parkinson’s disease and related disorders,” in: Handbook for Parkinson’s Disease, R. Pahwa and K. Lyons (eds.), Marcel Dekker Inc., New York (2007), 4th ed.

    Google Scholar 

  17. A. Quincozes-Santos, L. D. Bobermin, R. P. Tonial, et al., “Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions,” Eur. Arch. Psychiatry Clin. Neurosci., No. 6, 475–481 (2010).

  18. T. B. Rodrigues, N. Granado, O. Ortiz, et al., “Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated though D(1) dopamine receptors,” J. Neurosci. Res., No. 15, 3284–3293 (2007).

  19. J. Saura, R. Kettler, M. Da Prada, and J. G. Richards, “Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain,” J. Neurosci., No. 5, 1977–1999 (1992).

  20. R. E. See and C. E. Murray, “Changes in striatal dopamine release and metabolism during and after subchronic haloperidol administration in rats,” Neurosci. Lett., No. 1, 100–104 (1992).

  21. M. V. Sofroniew and H. V. Vinters, “Astrocytes; biology and pathology,” Acta Neuropathol., No. 1, 7–35 (2010).

  22. C. Song, A. Lin, G. Kenis, et al., “Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist,” Schizophr. Res., No. 2, 157–164 (2000).

  23. R. M. Villalba and Y. Smith, “Neuroglial plasticity at striatal glutamatergic synapses in Parkinson’s disease,” Front. Syst. Neurosci., 5 (2011).

  24. H. Wang, H. Xu, J. Niu, et al., “Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain,” Schizophr. Res., No. 1–3, 164–174 (2010).

  25. R. A. Webster, Neurotransmitters, Drugs and Brain Function, John Wiley & Sons, UK (2001).

    Book  Google Scholar 

  26. E. Zhuravliova, T. Barbakadze, N. Natsvlishvili, and D. G. Mikeladze, “Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity,” Neurochem. Int., No. 7–8, 976–982 (2007).

  27. J. Zou, Y. X. Wang, H. J. Mu, et al., “Down-regulation of glutamine synthetase enhances migration of rat astrocytes after in vitro injury,” Neurochem. Int., No. 3, 404–413 (2011).

Download references

Author information

Authors and Affiliations

  1. Scientific Neurology Center, Russian Academy of Medical Sciences, Moscow, Russia

    D. N. Voronkov, R. M. Khudoerkov & E. L. Dovedova

Authors
  1. D. N. Voronkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. M. Khudoerkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. L. Dovedova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. N. Voronkov.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 113, No. 7, Iss. 1, pp. 47–51, July, 2013.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Voronkov, D.N., Khudoerkov, R.M. & Dovedova, E.L. Changes in Neuroglial Interactions in Nigrostriatal Brain Structures on Modeling of Dopamine System Dysfunction. Neurosci Behav Physi 44, 1073–1077 (2014). https://doi.org/10.1007/s11055-014-0027-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-014-0027-y

Keywords

Search

Navigation